Effects of sodium-glucose cotransporter 2 inhibitors on cause-specific cardiovascular death in patients with CKD by Fletcher, RA, Herrington, WG, Agarwal, R, Mayne, KJ, Arnott, C, Jardine, MJ, Mahaffey, KW, Perkovic, V, Staplin, N, Wheeler, DC, Chertow, GM, Heerspink, HJL, Neuen, BL

Sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes: a SMART-C collaborative meta-analysis by Patel, SM, Kang, YM, Im, K, Neuen, BL, Anker, SD, Bhatt, DL, Butler, J, Cherney, DZI, Claggett, BL, Fletcher, RA, Herrington, WG, Inzucchi, SE, Jardine, MJ, Mahaffey, KW, McGuire, DK, McMurray, JJV, Neal, B, Packer, M, Perkovic, V, Solomon, SD, Staplin, N, Vaduganathan, M, Wanner, C, Wheeler, DC, Zannad, F, Zhao, Y, Heerspink, HJL, Sabatine, MS, Wiviott, SD

2017 cardiovascular and stroke endpoint definitions for clinical trials by Hicks, KA, Mahaffey, KW, Mehran, R, Nissen, SE, Wiviott, SD, Dunn, B, Solomon, SD, Marler, JR, Teerlink, JR, Farb, A, Morrow, DA, Targum, SL, Sila, CA, Hai, MT, Jaff, MR, Joffe, HV, Cutlip, DE, Desai, AS, Lewis, EF, Gibson, CM, Landray, MJ, Lincoff, AM, White, CJ, Brooks, SS, Rosenfield, K, Domanski, MJ, Lansky, AJ, McMurray, JJV, Tcheng, JE, Steinhubl, SR, Burton, P, Mauri, L, O'Connor, CM, Pfeffer, MA, Hung, HMJ, Stockbridge, NL, Chaitman, BR, Temple, RJ

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials by Hicks, KA, Mahaffey, KW, Mehran, R, Nissen, SE, Wiviott, SD, Dunn, B, Solomon, SD, Marler, JR, Teerlink, JR, Farb, A, Morrow, DA, Targum, SL, Sila, CA, Hai, MTT, Jaff, MR, Joffe, HV, Cutlip, DE, Desai, AS, Lewis, EF, Gibson, CM, Landray, MJ, Lincoff, AM, White, CJ, Brooks, SS, Rosenfield, K, Domanski, MJ, Lansky, AJ, McMurray, JJV, Tcheng, JE, Steinhubl, SR, Burton, P, Mauri, L, O'Connor, CM, Pfeffer, MA, Hung, HMJ, Stockbridge, NL, Chaitman, BR, Temple, RJ, Standardized Data Collection For Cardiovascular Trials Initiative (Scti)